First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    AstraZeneca PLC

    AZN · 22 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 22 macro, policy, and market developments to AstraZeneca PLC since 2026-08-28. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for AZN yet, so no modelled value is shown. The AZN valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run AZN on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for AZN. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer

      Direct revenue potential from new drug combination approval, expanding market share in NSCLC.

      · Moves peak sales estimates for tagrisso and orpathys, probability of success for pipeline assets, market share in nsclc

    • Main threat

      Ionis slides over 40% year-to-date following late-stage clinical setbacks

      Partnered drug development. Pelacarsen is a co-development program with AstraZeneca. Setbacks directly impact potential future milestone payments and shared profits.

      · Moves probability of success for pelacarsen, peak sales estimates for pelacarsen, future milestone payments from ions

    • Open question

      Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease

      Potential indirect competitive pressure or market dynamics shift in kidney disease treatment. While not directly involved in these specific drugs, AZN has a significant presence in renal and rare disease markets.

      · Moves market share for existing or pipeline kidney disease treatments, competitive landscape in renal disease

    What changed, by assumption

    Peak sales estimates for tagrisso and orpathys
    • 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
    Peak sales estimates for osimertinib (tagrisso)
    • 2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026
    • 2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial data
    Probability of success for pipeline assets
    • 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
    • 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
    • 2026-08-31HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China
    Peak sales estimates for tagrisso
    • 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
    Longevity and peak sales of osimertinib franchise
    • 2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-06Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-06Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-06RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerBullish3-12m0.60
    2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerBullish3-12m0.80
    2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerBullish3-12m0.70
    2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressBullish3-12m0.60
    2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialBearish3-12m0.30
    2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOBullish1-3m0.60
    2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026Bullish1-3m0.75
    2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney Diseasewatch3-12m0.30
    2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOBullish1-3m0.60
    2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026Bullish1-3m0.60
    2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenBearish3-12m0.20
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targetswatch3-12m0.30